e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
New drugs in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Penetration and pharmacokinetics of peramivir in upper and lower airway epithelia and plasma
Y. Funatsu, N. Hasegawa, H. Namkoong, T. Asami, H. Fujiwara, Y. Kimizuka, S. Tasaka, M. Ishii, F. Saito, K. Yagi, S. Iwata, T. Betsuyaku (Tokyo, Japan)
Source:
Annual Congress 2013 –New drugs in respiratory medicine
Session:
New drugs in respiratory medicine
Session type:
Poster Discussion
Number:
1596
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Funatsu, N. Hasegawa, H. Namkoong, T. Asami, H. Fujiwara, Y. Kimizuka, S. Tasaka, M. Ishii, F. Saito, K. Yagi, S. Iwata, T. Betsuyaku (Tokyo, Japan). Penetration and pharmacokinetics of peramivir in upper and lower airway epithelia and plasma. Eur Respir J 2013; 42: Suppl. 57, 1596
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Laninamivir’s prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Interaction between RPL554 and glycopyrronium bromide in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Allergen exposed primary human bronchial epithelial cells have inhibited transport of salbutamol sulphate only when functional organic cation tranporters are present
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229
Year: 2004
Population pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infection
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010
Effect of N-acetylcysteine on the activity of antibiotics against relevant respiratory pathogens
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Immunoregulatory effects of ceftaroline in airway epithelial cells and in immunocompetent cells
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Differential effects of budesonide and fluticasone propionate on expression of lactotransferrin in airway epithelium
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effects of prednisone associated or not to bronchial section on mucocilliary clearance
Source: Annual Congress 2009 - Lung transplantation: pre- and postoperative problems
Year: 2009
Comparison of pentamidine inhaled dose with two different nebulizers
Source: International Congress 2014 – Respiratory infections in children
Year: 2014
Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Airway surface liquid concentrations of aztreonam lysine for inhalation in children with cystic fibrosis: A modeling study
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept